

AF  
Patent  
Attorney Docket No. 1003301-000914

TFW  
\$1653  
ce

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)	Group Art Unit: 1653
Kjell OLMARKER	)	Examiner: ROBERT B. MONDESI
Application No.: 10/092,919	)	Confirmation No.: 1488
Filing Date: March 8, 2002	)	
Title: NOVEL USE OF CYTOKINE	)	
INHIBITORS	)	

**SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is a SUPPLEMENTAL Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.

- ☐ No additional fee for submission of an IDS is required.
- ☐ The fee of 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☒ A statement under 37 C.F.R. § 1.97(e), and the fee of 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the fee due.
- ☒ Charge \$180.00 to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date July 20, 2006

By:

Benton S. Duffett, Jr.

Benton S. Duffett, Jr.  
Registration No. 22030

P.O. Box 1404  
Alexandria, VA 22313-1404  
703 836 6620

## 180.00 04'

The \$180.00 fee pursuant to 37 C.F.R. §1.17(p) is submitted herewith.

To assist the Examiner, the document D6 is listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned once this document is considered.


The further examination and allowance of this application are respectfully requested.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: July 20, 2006

By:



Benton S. Duffett, Jr.  
Registration No. 22030


P.O. Box 1404  
Alexandria, VA 22313-1404  
703 836 6620

**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application	10/092,919
Filing Date	March 8, 2002
First Named Inventor	Kjell OLMARKER
Examiner Name	Robert B. Mondesi
Attorney Docket No.	1003300-000914

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Black L.E. "Pharmacology review of infliximab BLA" - 21-05-1998-found at internet address:
	<a href="http://www.fda.gov/cder/biologics/review/inflcen082498r4.pdf">http://www.fda.gov/cder/biologics/review/inflcen082498r4.pdf</a>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.